Bausch & Lomb achieves 6% revenue growth in Q3 2025, driven by robust performance in pharmaceuticals and premium IOLs, with optimistic guidance ahead.

Good morning and welcome to Bausch & Lomb's third quarter 2025 earnings call. All participants will be in a listen only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touchtone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to George Gadkowski, Vice President of Investor Relations and Business Insights. Please go ahead.

Thank you. Good morning everyone and welcome to our third quarter 2025 financial results conference call. Participating on today's call are Chairman and Chief Executive Officer Mr. Brent Saunders and Chief Financial Officer Mr. Sam Aldousari. In addition to this live webcast, a copy of today's slide presentation and a replay of this conference call will be available on our website under the Investor Relations section. Before we begin, I would like to remind you that our presentation today contains forward looking information. We would ask that you take a moment to read the forward looking legend at the beginning of our presentation as it contains important information. This presentation contains non GAAP financial measures and ratios. For more information about these measures and ratios, please refer to slide one of the presentation. Non GAAP reconciliations can be found in the appendix to the presentation posted on our website. The financial guidance in this presentation is effective as of today only. It is our policy to generally not update guidance until the following quarter unless required by law and not to update or affirm guidance other than through broadly disseminated public disclosure. With that, it's my pleasure to turn the call over to Brent.

Thank you, George. And good morning to everyone joining us today. I'm going to provide an overview of our impressive third quarter performance and speak to how our strategy and patience is paying off. Sam will go deeper on the financials and update 2025 guidance. And I'll close with a look at products driving growth and opportunity. I'd like to thank my 13,000 colleagues around the world up front because without their commitment and belief in what we can achieve together, we'd be stuck in neutral. Instead, we're delivering on the vision we laid out in 2023. 6% constant currency revenue growth was once again fueled by a base business engine that continues to hump and the steady introduction of innovative products across categories. Pharmaceuticals was a standout thanks to 84 million in MIEBO revenue. Mibo growth helped bolster our comprehensive dry eye portfolio which is front and center for eye care professionals and patients and consumers. Effective selling has also meant more surgeons implanting invista intraocular lenses, helping drive 27% constant currency revenue growth in premium IOLs. Our loaded and differentiated pipeline will be on full display in just a few weeks at Investor Day. Importantly, the pipeline products we'll highlight aren't aspirational. These are clinical stage programs with anticipated launches over the next several years. Every part of our nearly three year journey since I returned, SEO has been aligned to one or more of three categories you've all become familiar with selling Excellence, Operational Excellence, and disruptive Innovation. Those aren't optional, they're imperatives. While our journey is nowhere near complete, given how far we've come, we've introduced a fourth category, Financial Excellence. This is our opportunity to deliver sustained, profitable growth that reflects our real potential. We'll show you what that looks like at Investor Day when we share our three year plan. We've reached a pivotal point in our journey to becoming the best iHealth company. Being the best means elevating the standard of care in eye health, which is why our priority.